12/17
09:21 am
bbio
GondolaBio and n-Lorem Foundation Partner to Advance Novel ASO Therapies for Genetic Diseases [Yahoo! Finance]
Low
Report
GondolaBio and n-Lorem Foundation Partner to Advance Novel ASO Therapies for Genetic Diseases [Yahoo! Finance]
12/16
08:06 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.
12/13
07:18 am
bbio
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Low
Report
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
12/3
08:13 am
bbio
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology [Yahoo! Finance]
Low
Report
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology [Yahoo! Finance]
11/29
03:58 pm
bbio
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More [Yahoo! Finance]
Neutral
Report
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More [Yahoo! Finance]
11/26
12:57 pm
bbio
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug [Yahoo! Finance]
Low
Report
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug [Yahoo! Finance]
11/25
06:26 pm
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Scotiabank from $45.00 to $48.00. They now have a "sector outperform" rating on the stock.
Medium
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Scotiabank from $45.00 to $48.00. They now have a "sector outperform" rating on the stock.
11/25
09:10 am
bbio
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market [Yahoo! Finance]
Medium
Report
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market [Yahoo! Finance]
11/25
08:27 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Bank of America Co. from $42.00 to $45.00. They now have a "buy" rating on the stock.
Medium
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Bank of America Co. from $42.00 to $45.00. They now have a "buy" rating on the stock.
11/25
08:04 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at HC Wainwright from $43.00 to $49.00. They now have a "buy" rating on the stock.
Medium
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at HC Wainwright from $43.00 to $49.00. They now have a "buy" rating on the stock.
11/22
07:59 pm
bbio
BridgeBio heart drug approved by FDA, setting up battle with Pfizer [Yahoo! Finance]
High
Report
BridgeBio heart drug approved by FDA, setting up battle with Pfizer [Yahoo! Finance]
11/22
07:16 pm
bbio
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (=90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients [Yahoo! Finance]
High
Report
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (=90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients [Yahoo! Finance]
11/22
07:11 pm
bbio
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (=90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
High
Report
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (=90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
11/19
02:49 pm
bbio
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market [Yahoo! Finance]
Low
Report
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market [Yahoo! Finance]
11/19
06:25 am
bbio
The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically [Yahoo! Finance]
Low
Report
The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically [Yahoo! Finance]
11/18
11:28 am
bbio
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months [Yahoo! Finance]
Medium
Report
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months [Yahoo! Finance]
11/18
11:15 am
bbio
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
Low
Report
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
11/18
05:31 am
bbio
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia [Yahoo! Finance]
Medium
Report
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia [Yahoo! Finance]
11/18
05:30 am
bbio
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
Medium
Report
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
11/15
12:19 pm
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Scotiabank from $44.00 to $45.00. They now have a "sector outperform" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Scotiabank from $44.00 to $45.00. They now have a "sector outperform" rating on the stock.
11/14
05:32 am
bbio
BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Medium
Report
BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
11/12
09:54 am
bbio
BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Medium
Report
BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/12
07:30 am
bbio
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
Medium
Report
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
11/5
07:30 am
bbio
BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
Low
Report
BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
10/25
08:37 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $43.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $43.00 price target on the stock.